- Incyte (INCY, Financial) to present data from its oncology portfolio at the 2025 ASCO Annual Meeting.
- Key studies include INCB123667 for ovarian cancer and Pemigatinib for glioblastoma.
- Presentations to cover treatments for squamous cell anal cancer, ovarian cancer, and myelofibrosis.
Incyte (INCY) has announced that it will showcase multiple abstracts featuring new data from its oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3 in Chicago. The presentations aim to highlight Incyte's ongoing efforts to innovate cancer care, focusing on some of the most challenging cancers and hematological diseases.
Among the highlights is an oral presentation on INCB123667, a selective CDK2 inhibitor, detailing safety and preliminary efficacy from a Phase 1 study in patients with advanced platinum-resistant and refractory ovarian cancer. This will be shared under the Gynecologic Cancer session on June 3.
Another significant study is the Phase 2 investigation of Pemigatinib, which will disclose results for glioblastoma or other gliomas with FGFR1-3 alterations, part of the FIGHT-209 study. These findings will be presented during the Central Nervous System Tumors session on May 30.
Additional poster presentations will cover the use of Retifanlimab in treating squamous cell carcinoma of the anal canal and Merkel cell carcinoma. These include insights from the POD1UM-303 trial and long-term outcomes from the POD1UM-201 trial.
Incyte's diverse oncology portfolio continues to advance with treatments such as INCB057643 for myelofibrosis, reflected in their clinical presentations at ASCO 2025. The company remains committed to transforming cancer treatment and enhancing patient outcomes globally.
